


<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648



### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	5,529,774	06/25/1996	Barba et al.	424	93.21	
	AB	5,585,096	12/17/1996	Martuza et al.	424	93.2	
	AC	5,585,254	12/17/1996	Maxwell et al.	435	465	
	AD	5,601,818	02/11/1997	Freeman et al.	424	93.21	
	AE	5,674,729	10/07/1997	Wimmer et al.	435	235.1	
	AF	5,681,731	10/28/1997	Lebkowski et al.	435	457	
	AG	5,688,773	11/18/1997	Chiocca et al.	514	44	
	AH	5,972,706	10/26/1999	Francis McCormick	435	440	
	AI	6,060,316	05/19/2000	Young et al.	435	455	
	AJ	6,110,461	08/29/2000	Lee et al.	424	93.6	
	AK	6,136,307	10/24/2000	Lee et al.	424	93.6	
	AL	6,264,940	07/24/2001	Gromeier et al.	424	93.2	
	AM	6,261,555	07/17/2001	Lee et al.	424	93.6	

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	AN	2005201079	04/07/2005	AU			NO
	AO	2004202292	06/17/2004	AU			NO
	AP	2004203458	08/26/2004	AU			NO
	AQ	2003258060	10/13/2003	AU			NO

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	AR	2001/784776	10/18/2001	AU			NO
	AS	2001770517	06/04/2001	AU			NO
	AT	2001782020	05/30/2001	AU			NO
	AU	2001776061	05/30/2001	AU			NO
	AV	2001782402	04/17/2001	AU			NO
	AW	2000776401	09/14/2000	AU			NO
	AX	1998726500	09/22/1998	AU			NO
	AY	1994699487	11/21/1994	AU			NO
	AZ	1996699811	12/30/1996	AU			NO
	BA	20011268146	12/11/2001	AU			NO
	BB	2 051 289	03/15/1992	CA			NO
	BC	1032269	09/06/2000	EP			NO
	BD	WO 2005/107474	11/17/2005	PCT			NO
	BE	WO 2000/008166	02/17/2000	PCT			NO
	BF	WO 1999/045783	09/16/1999	PCT			NO
	BG	WO 1999/018799	04/22/1999	PCT			NO
	BH	WO 1994/018992	09/01/1999	PCT			NO
	BI	WO 1993/009221	05/13/1993	PCT			NO
	BJ	WO 1990/012087	10/18/1990	PCT			NO
	BK	WO 2006/047301	05/04/2006	PCT			NO
	BL	WO 2005/002607	01/13/2005	PCT			NO
	BM	WO 2003/082200	10/09/2003	PCT			NO

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	BN	WO 2002/091997	11/21/2002	PCT			NO
	BO	WO 2001/53506	07/26/2001	PCT			NO
	BP	WO 2006/002394	01/05/2006	PCT			NO
	BQ	WO 2004/003562	01/08/2004	PCT			NO
	BR	WO 2003/073918	09/12/2003	PCT			NO
	BS	WO 2002/087625	11/07/2002	PCT			NO
	BT	WO 2001/19380	03/22/2001	PCT			NO
	BU	WO 2005/087931	09/22/2005	PCT			NO
	BV	WO 2003/094938	11/20/2003	PCT			NO
	BW	WO 2003/010306	02/06/2003	PCT			NO
	BX	WO 2005/007824	01/27/2005	PCT			NO
	BY	WO 2003/092579	11/13/2003	PCT			NO
	BZ	WO 2003/008586	01/30/2003	PCT			NO
	CA	WO 2002/43647	06/06/2002	PCT			NO
	CB	WO 2005/087931	09/22/2005	PCT			NO
	CC	WO 2005/030139	04/07/2005	PCT			NO
	CD	WO 2004/054613	07/01/2004	PCT			NO
	CE	WO 2002/092826	11/21/2002	PCT			NO
	CF	WO 2002/50304	06/27/2002	PCT			NO
	CG	WO 2002/43647	06/06/2002	PCT			NO
	CH	WO 2001/04334	01/18/2001	PCT			NO
	CI	WO 2001/12815	02/22/2001	PCT			NO

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	CJ	WO 2000/62735	10/26/2000	PCT			NO
	CK	WO 1999/18799	04/22/1999	PCT			NO
	CL	WO 1996/00007	01/04/1996	PCT			NO
	CM	WO 1994/18992	09/01/1994	PCT			NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**

	CN	Anastassiou, G. <i>et al</i> "Expression of VLA-2, VLA-3 and $\alpha_v$ integrin receptors in ureal melanoma: association with microvascular architecture of the tumour and prognostic value". <i>Br. J. Ophthalmol.</i> 2000; 84:899-902.
	CO	Casasnovas, J.M. and Springer, T.A. "Pathway of Rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released" <i>Journal of Virology</i> 1994; Vol. 68(9): 5882-5889.
	CP	Daraï, E. <i>et al</i> "Soluble adhesion molecule in serum and cyst fluid from patients with cystic tumours of the ovary", <i>Human Reproduction</i> , 13(10):2831-2835, 1998.
	CQ	DeTulleo, L. and Kirchhausen, T. "The clathrin endocytic pathway in viral infection", <i>The EMBO Journal</i> , 17 (16): 4585-4593, 1998.
	CR	Fiucci, G. <i>et al</i> "Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells" <i>Oncogene</i> (2002) 21: 2365-2375.
	CS	Greve, J.M. <i>et al</i> "Mechanisms of receptor-mediated Rhinovirus neutralization defined by two soluble forms of ICAM-1", <i>Journal of Virology</i> , 1991, 65(11):6015-6023
	CT	Kang, X. <i>et al</i> "Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer" <i>World Journal of Gastroenterology</i> 2005; 11(27):4250-4253.
	CU	Lonberg-Holm, K., <i>et al</i> "Unrelated animal viruses share receptors" <i>Nature</i> 1976, 259:679-681.

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

4  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

	<b>CV</b>	Marjomäki, V., <i>et al</i> "Internalization of Echovirus 1 in Caveolae" <i>Journal of Virology</i> , 2002, 76(4):1856-1865.
	<b>CW</b>	Martin, S. <i>et al</i> "Efficient neutralization and disruption of Rhinovirus by chimeric ICAM-1/Immunoglobulin molecules", <i>Journal of Virology</i> , 1993, 67(6):3561-3568.
	<b>CX</b>	Nasu, K. <i>et al</i> "Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and the expression of ICAM-1 mRNA in uterine cervical cancer" 1997 <i>Gynecol. Oncol.</i> Vol. 65(2): 304-308.
	<b>CY</b>	Newcombe, N.G. <i>et al</i> . "Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection" <i>Journal of Virology</i> , 2004, 78(3):1431-1439.
	<b>CZ</b>	Newcombe, N.G. <i>et al</i> . "Cellular receptor interactions of the C-cluster human group A coxsackieviruses" <i>Journal of General Virology</i> , 2003, 84:3041-3050.
	<b>DA</b>	Pui, C.H. <i>et al</i> "Serum intercellular adhesion molecule-1 in childhood malignancy" <i>Blood</i> , 82(3):895-898, 1993.
	<b>DB</b>	Schaefer, M. <i>et al</i> , "Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha" <i>Brain Behav. Immuno</i> 2004, 18(6): 555-562.
	<b>DC</b>	Shafren, D.R. <i>et al</i> "Antibody binding to individual short consensus repeats of decay-accelerating factor enhances Enterovirus cell attachment and infectivity". <i>The Journal of Immunology</i> 1998, 160:2318-2323.
	<b>DD</b>	Shafren, D. R. <i>et al</i> "Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection," <i>Journal of General Virology</i> 2000, 81:889-894
	<b>DE</b>	Taguchi, O. <i>et al</i> "Circulating intercellular adhesion molecule-1 in patients with lung cancer" 1997 <i>Intern. Med.</i> Vol. 36(1): 14-18
	<b>DF</b>	Triantafilou, M. <i>et al</i> "Identification of Echovirus 1 and Coxsackievirus A9 receptor molecules via a nosed flow cytometric quantification method" <i>Cytometry</i> 43:279-289 (2001)

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  <div style="text-align: right;">10/17/2008</div>
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

5

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

	<b>DG</b>	van den Engel, N.K. <i>et al</i> "Oral DNA vaccination with a plasmid encoding soluble ICAM-1 modulates cytokine expression profiles in nonobese diabetic mice". <i>J. Mol. Med.</i> 2002, May; 80(5): 301-308.
--	-----------	---


<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Form 1449

6

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648



### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	5,529,774	06/25/1996	Barba et al.	424	93.21	
	AB	5,585,096	12/17/1996	Martuza et al.	424	93.2	
	AC	5,585,254	12/17/1996	Maxwell et al.	435	465	
	AD	5,601,818	02/11/1997	Freeman et al.	424	93.21	
	AE	5,674,729	10/07/1997	Wimmer et al.	435	235.1	
	AF	5,681,731	10/28/1997	Lebkowski et al.	435	457	
	AG	5,688,773	11/18/1997	Chiocca et al.	514	44	
	AH	5,972,706	10/26/1999	Francis McCormick	435	440	
	AI	6,060,316	05/19/2000	Young et al.	435	455	
	AJ	6,110,461	08/29/2000	Lee et al.	424	93.6	
	AK	6,136,307	10/24/2000	Lee et al.	424	93.6	
	AL	6,264,940	07/24/2001	Gromeier et al.	424	93.2	
	AM	6,261,555	07/17/2001	Lee et al.	424	93.6	

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	AN	2005201079	04/07/2005	AU			NO
	AO	2004202292	06/17/2004	AU			NO
	AP	2004203458	08/26/2004	AU			NO
	AQ	2003258060	10/13/2003	AU			NO

<b>EXAMINER</b>  WEST21444163.1 580850-000004	/Bao Li/	<b>DATE CONSIDERED</b>  10/17/2008
--	----------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	AR	2001/784776	10/18/2001	AU			NO
	AS	2001770517	06/04/2001	AU			NO
	AT	2001782020	05/30/2001	AU			NO
	AU	2001776061	05/30/2001	AU			NO
	AV	2001782402	04/17/2001	AU			NO
	AW	2000776401	09/14/2000	AU			NO
	AX	1998726500	09/22/1998	AU			NO
	AY	1994699487	11/21/1994	AU			NO
	AZ	1996699811	12/30/1996	AU			NO
	BA	20011268146	12/11/2001	AU			NO
	BB	2 051 289	03/15/1992	CA			NO
	BC	1032269	09/06/2000	EP			NO
	BD	WO 2005/107474	11/17/2005	PCT			NO
	BE	WO 2000/008166	02/17/2000	PCT			NO
	BF	WO 1999/045783	09/16/1999	PCT			NO
	BG	WO 1999/018799	04/22/1999	PCT			NO
	BH	WO 1994/018992	09/01/1999	PCT			NO
	BI	WO 1993/009221	05/13/1993	PCT			NO
	BJ	WO 1990/012087	10/18/1990	PCT			NO
	BK	WO 2006/047301	05/04/2006	PCT			NO
	BL	WO 2005/002607	01/13/2005	PCT			NO
	BM	WO 2003/082200	10/09/2003	PCT			NO

<b>EXAMINER</b> WEST21444163.1 580850-000004	/Bao Li/  DATE CONSIDERED 10/17/2008
--	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449



<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	BN	WO 2002/091997	11/21/2002	PCT			NO
	BO	WO 2001/53506	07/26/2001	PCT			NO
	BP	WO 2006/002394	01/05/2006	PCT			NO
	BQ	WO 2004/003562	01/08/2004	PCT			NO
	BR	WO 2003/073918	09/12/2003	PCT			NO
	BS	WO 2002/087625	11/07/2002	PCT			NO
	BT	WO 2001/19380	03/22/2001	PCT			NO
	BU	WO 2005/087931	09/22/2005	PCT			NO
	BV	WO 2003/094938	11/20/2003	PCT			NO
	BW	WO 2003/010306	02/06/2003	PCT			NO
	BX	WO 2005/007824	01/27/2005	PCT			NO
	BY	WO 2003/092579	11/13/2003	PCT			NO
	BZ	WO 2003/008586	01/30/2003	PCT			NO
	CA	WO 2002/43647	06/06/2002	PCT			NO
	CB	WO 2005/087931	09/22/2005	PCT			NO
	CC	WO 2005/030139	04/07/2005	PCT			NO
	CD	WO 2004/054613	07/01/2004	PCT			NO
	CE	WO 2002/092826	11/21/2002	PCT			NO
	CF	WO 2002/50304	06/27/2002	PCT			NO
	CG	WO 2002/43647	06/06/2002	PCT			NO
	CH	WO 2001/04334	01/18/2001	PCT			NO
	CI	WO 2001/12815	02/22/2001	PCT			NO

<b>EXAMINER</b>  WEST21444163.1 580850-000004	/Bao Li/	<b>DATE CONSIDERED</b>  10/17/2008
--	----------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

EXAM. INITIALS		DOCUMENT NUMBER	DATE (mm/dd/yyyy)	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	CJ	WO 2000/62735	10/26/2000	PCT			NO
	CK	WO 1999/18799	04/22/1999	PCT			NO
	CL	WO 1996/00007	01/04/1996	PCT			NO
	CM	WO 1994/18992	09/01/1994	PCT			NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**

	CN	Anastassiou, G. <i>et al</i> "Expression of VLA-2, VLA-3 and $\alpha_v$ integrin receptors in ureal melanoma: association with microvascular architecture of the tumour and prognostic value". <i>Br. J. Ophthalmol.</i> 2000; 84:899-902.
	CO	Casasnovas, J.M. and Springer, T.A. "Pathway of Rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released" <i>Journal of Virology</i> 1994; Vol. 68(9): 5882-5889.
	CP	Darai, E. <i>et al</i> "Soluble adhesion molecule in serum and cyst fluid from patients with cystic tumours of the ovary", <i>Human Reproduction</i> , 13(10):2831-2835, 1998.
	CQ	DeTulleo, L. and Kirchhausen, T. "The clathrin endocytic pathway in viral infection", <i>The EMBO Journal</i> , 17 (16): 4585-4593, 1998.
	CR	Fiucci, G. <i>et al</i> "Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells" <i>Oncogene</i> (2002) 21: 2365-2375.
	CS	Greve, J.M. <i>et al</i> "Mechanisms of receptor-mediated Rhinovirus neutralization defined by two soluble forms of ICAM-1", <i>Journal of Virology</i> , 1991, 65(11):6015-6023
	CT	Kang, X. <i>et al</i> "Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer" <i>World Journal of Gastroenterology</i> 2005; 11(27):4250-4253.
	CU	Lonberg-Holm, K., <i>et al</i> "Unrelated animal viruses share receptors" <i>Nature</i> 1976, 259:679-681.

<b>EXAMINER</b>  WEST21444163.1 580850-000004	/Bao Li/  <b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

	<b>CV</b>	Marjomäki, V., <i>et al</i> "Internalization of Echovirus 1 in Caveolae" <i>Journal of Virology</i> , 2002, 76(4):1856-1865.
	<b>CW</b>	Martin, S. <i>et al</i> "Efficient neutralization and disruption of Rhinovirus by chimeric ICAM-1/Immunoglobulin molecules", <i>Journal of Virology</i> , 1993, 67(6):3561-3568.
	<b>CX</b>	Nasu, K. <i>et al</i> "Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and the expression of ICAM-1 mRNA in uterine cervical cancer" 1997 <i>Gynecol. Oncol.</i> Vol. 65(2): 304-308.
	<b>CY</b>	Newcombe, N.G. <i>et al</i> . "Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection" <i>Journal of Virology</i> , 2004, 78(3):1431-1439.
	<b>CZ</b>	Newcombe, N.G. <i>et al</i> . "Cellular receptor interactions of the C-cluster human group A coxsackieviruses" <i>Journal of General Virology</i> , 2003, 84:3041-3050.
	<b>DA</b>	Pui, C.H. <i>et al</i> "Serum intercellular adhesion molecule-1 in childhood malignancy" <i>Blood</i> , 82(3):895-898, 1993.
	<b>DB</b>	Schaefer, M. <i>et al</i> , "Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha" <i>Brain Behav. Immuno</i> 2004, 18(6): 555-562.
	<b>DC</b>	Shafren, D.R. <i>et al</i> "Antibody binding to individual short consensus repeats of decay-accelerating factor enhances Enterovirus cell attachment and infectivity". <i>The Journal of Immunology</i> 1998, 160:2318-2323.
	<b>DD</b>	Shafren, D. R. <i>et al</i> "Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection," <i>Journal of General Virology</i> 2000, 81:889-894
	<b>DE</b>	Taguchi, O. <i>et al</i> "Circulating intercellular adhesion molecule-1 in patients with lung cancer" 1997 <i>Intern. Med.</i> Vol. 36(1): 14-18
	<b>DF</b>	Triantafyllou, M. <i>et al</i> "Identification of Echovirus 1 and Coxsackievirus A9 receptor molecules via a nosed flow cytometric quantification method" <i>Cytometry</i> 43:279-289 (2001)

<b>EXAMINER</b>  WEST21444163.1 580850-000004	/Bao LV/	<b>DATE CONSIDERED</b>  10/17/2008
--	----------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SPRUSON1100	<b>Serial No.:</b> 10/539,219
	<b>Applicant(s):</b> Darren R. Shafren	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 17, 2006	<b>Group Art Unit:</b> 1648

	<b>DG</b>	van den Engel, N.K. <i>et al</i> "Oral DNA vaccination with a plasmid encoding soluble ICAM-1 modulates cytokine expression profiles in nonobese diabetic mice". <i>J. Mol. Med.</i> 2002, May; 80(5): 301-308.
--	-----------	---

<b>EXAMINER</b>  WEST21444163.1 580850-000004	<b>DATE CONSIDERED</b>  10/17/2008
--	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Form 1449




**PATENT ATTORNEY DOCKET NO.: SPRUSON1100**

The Patent and Trademark Office date stamp sets forth the receipt date of:

**Applicant:** Darren R. Shafren  
**Serial No.:** 10/539219  
**Filing Date:** January 17, 2006  
**Title:** METHOD OF TREATING A MALIGNANCY IN A SUBJECT VIA DIRECT  
PICORNAVIRAL-MEDIATED ONCOLYSIS

**INFORMATION DISCLOSURE STATEMENT**

1. Transmittal Letter (2 pgs.)
2. Information Disclosure Statement (2 pgs.)
3. Form PTO-1449 (6 pgs.)
4. Seventy-Two (72) References
5. Return Receipt Postcard



**Atty/Sec Initials:** AMN:cls

**Client/Matter No.:** 580850-5

**Date Mailed:** 08/21/2008

**Date Due:** N/A

Box 2 of 2